Form 4: Mirum Pharmaceuticals Executive Receives Stock Grant
Insider Transaction (Form 4)
Robert Paul Myers, Chief Medical Officer of Mirum Pharmaceuticals, Inc., reported multiple transactions in common stock on October 9, 2026.
Summary
- Grant/award: acquired 40,000 Employee Stock Option (right to buy) on October 9, 2026; holds 40,000 after (Direct).
- Grant/award: acquired 25,000 Restricted Stock Units on October 9, 2026; holds 25,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Robert Paul Myers — Officer (Chief Medical Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-09 | Grant/award | Employee Stock Option (right to buy) | 40,000 | — | — | 40,000 |
| 2026-10-09 | Grant/award | Restricted Stock Units | 25,000 | — | — | 25,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-09 | Grant/award (40,000 shares) |
| 2026-10-09 | Grant/award (25,000 shares) |
Keywords
insider transaction, Form 4, MIRM, Mirum Pharmaceuticals, Inc., neutral, Robert Paul Myers
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.